T. Rowe Price Investment Management, Inc. 13D and 13G filings for Apellis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 1:28 pm Sale | 2024-09-30 | 13G | Apellis Pharmaceuticals, Inc. APLS | T. Rowe Price Investment Management, Inc. | 2,985,272 2.500% | -3,318,312 (-52.64%) | Filing |
| 2024-02-14 10:04 am Purchase | 2023-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | T. Rowe Price Investment Management, Inc. | 6,303,584 5.300% | 460,924 (+7.89%) | Filing |
| 2023-02-14 12:40 pm Purchase | 2022-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | T. Rowe Price Investment Management, Inc. | 5,842,660 5.300% | 5,842,660 (New Position) | Filing |